Yazar "Erbahceci, Inci Elif" seçeneğine göre listele

Listeleniyor 1 - 3 / 3
  • [ X ]
    Öğe
    Corneal and Conjunctival Sensitivity Changes Following Intravitreal Ranibizumab Injection in Diabetic Retinopathy
    (Mary Ann Liebert, Inc, 2015) Ornek, Nurgul; Ornek, Kemal; Erbahceci, Inci Elif
    Purpose: To evaluate corneal and conjunctival sensitivity changes following intravitreal ranibizumab (IVR) injection in eyes with diabetic retinopathy. Methods: Forty-six eyes of 46 patients with diabetic macular edema who underwent intravitreal injection of ranibizumab were included in this prospective study. Fifty eyes of 50 type 2 diabetes mellitus patients served as controls. Each participant underwent a complete ophthalmological examination. Fundus florescein angiography and optical coherence tomography were performed to assess the posterior segment details. IVR (0.5 mg/0.05 mL) was injected from the lower temporal quadrant. Corneal and conjunctival sensitivities were measured using the Cochet-Bonnet esthesiometer. Results: Corneal sensitivity (CS) increased significantly on the first day in temporal and nasal corneas in treated eyes (P=0.005 and P=0.000, respectively). At week one the increase continued and the difference was significant in central, temporal, and nasal corneas (all P=0.000). In fellow eyes, CS increased significantly only in nasal cornea (P=0.004). Only nasal conjunctival sensitivity increased significantly both in treated and fellow eyes at week one (P=0.000 and P=0.005, respectively). Conclusion: IVR may have a potential to increase corneal and conjunctival sensitivities in diabetic retinopathy.
  • Küçük Resim
    Öğe
    Effect of intravitreal bevacizumab on retrobulbar blood flow of patients with diabetic macular edema
    (Wichtig Publ, 2015) Örnek, Nurgül; İnal, Mikail; Erbahceci, Inci Elif; Oğurel, Tevfik; Örnek, Kemal
    Purpose: To determine the effect of intravitreal bevacizumab on retrobulbar blood flow of patients with diabetic macular edema. Methods: Peak systolic velocity, end-diastolic velocity, resistance, and pulsatility indices of central retinal artery (CRA), nasal posterior ciliary artery (NPCA), temporal posterior ciliary artery (TPCA), and ophthalmic artery (OA) were assessed by color Doppler ultrasonography in injected and uninjected eyes of 37 patients at baseline and at day 1 and day 7 after the injection. Results: At day 1 after the injection, peak systolic and end diastolic velocities of the CRA and NPCA in the injected eyes and peak systolic velocity of NPCA in the uninjected eyes decreased significantly (p<0.05, p = 0.025, respectively). Peak systolic and end diastolic velocities were not significantly different in the injected and uninjected eyes at day 7 after the injection (p>0.05). In the injected eyes, there was no significant change in resistance and pulsatility indices (p>0.05), but a decrease in resistance index of NPCA and resistance and pulsatility indices of TPCA occurred in uninjected eyes at day 7 after the injection (p = 0.016, p = 0.023, and p = 0.025, respectively). Conclusions: Intravitreal bevacizumab affects retrobulbar blood flow in injected and uninjected eyes of patients with diabetic macular edema.
  • Küçük Resim
    Öğe
    Intravitreal Dexamethasone Implant (Ozurdex) for Refractory Macular Edema Secondary to Retinitis Pigmentosa
    (Turkish Ophthalmological Soc, 2016) Ornek, Nurgul; Ornek, Kemal; Erbahceci, Inci Elif
    Macular edema (ME) in retinitis pigmentosa (RP) often impairs central vision dramatically. A 41-year-old woman diagnosed with RP was referred to our outpatient clinic due to severe visual deterioration in both eyes. The patient was treated with topical carbonic anhydrase inhibitors, topical corticosteroids and intravitreal triamcinolone acetonide injections, but her ME recurred. Intravitreal 0.7 mg dexamethasone implant (Ozurdex, Allergan) was administered into both eyes without complications. On the fourth day after both injections, visual acuity improved and ME almost totally resolved. No recurrence was observed at follow-up six months later.